Endocrinology | Home | MIMS Malaysia

Endocrinology

Lanifibranor efficacy in NASH evident in diabetics and non-diabetics

Roshini Claire Anthony, 13 hours ago

The efficacy of lanifibranor in reducing histological markers of non-alcoholic steatohepatitis (NASH) is comparable in patients with and without type 2 diabetes (T2D), according to the phase IIb NATIVE study presented as a poster at AASLD 2020.

Overweight from childhood to adulthood ups risks of hypertensive disorders in pregnancy

Yesterday

Body mass index (BMI) values that are above average and the development of overweight from childhood to adulthood are risk factors for gestational hypertension and pre-eclampsia, but normalizing BMI from childhood to conception reduces such risks, according to a study.

Moderate physical activity lowers diabetes risk in older adults

Yesterday

Accelerometer-assessed moderate-to-vigorous physical activity (MVPA) at baseline shows an inverse relationship with incident diabetes among individuals aged ≥50 years, a recent study involving a US Hispanic/Latino population has found.

High glucose predicts poor outcomes after endovascular treatment for stroke

Yesterday

Patients with acute ischaemic stroke undergoing endovascular treatment are at heightened risk of poor functional outcome and symptomatic intracranial haemorrhage (sICH) in the presence of hyperglycaemia at admission, a study has found.

Rosacea linked to hypertension, dyslipidaemia

Stephen Padilla, 2 days ago

Rosacea, a chronic inflammatory cutaneous disorder associated with multiple systemic illnesses, is associated with hypertension and dyslipidaemia but not with ischaemic heart disease (IHD), stroke, or diabetes, results of a systematic review and meta-analysis have shown.

Durable treatment response seen with dapagliflozin-saxagliptin add-on in T2D patients on metformin

Audrey Abella, 2 days ago

Reductions in liver fat and adipose tissue volumes were sustained in patients with type 2 diabetes (T2D) with the addition of the SGLT-2* inhibitor dapagliflozin (DAPA) and the DPP-4** inhibitor saxagliptin (SAXA) to metformin (MET), compared with a regimen comprising glimepiride (GLIM)+MET, according to the extension period results of a phase IIIb trial.

Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes

Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Empagliflozin: Another SGLT-2i in HFrEF armamentarium

Roshini Claire Anthony, 05 Nov 2020

Adding empagliflozin to recommended therapy in patients with heart failure with reduced ejection fraction (HFrEF) reduced the risk of HF hospitalization and slowed renal function decline, the EMPEROR-Reduced* trial showed.

The FreeStyle Libre system: A new tool for GPs managing diabetes

26 Oct 2020

An estimated 463 million adults – about one in 11 – had diabetes in 2019. These numbers are expected to rise to 700 million by 2045. Worse, one in two people are undiagnosed. [https://www.idf.org/, accessed 19 October 2020]

NCDs continue with march in the shadow of COVID-19

Pank Jit Sin, 02 Sep 2020

The most recent report by the National Health and Morbidity Survey (NHMS) 2019 proved to be a blow to public health in Malaysia. Even with consistent, unrelenting efforts by stakeholders and policymakers, the figures for NCDs continue to climb. MIMS Doctor reached out to the Director-General of Health Tan Sri Dato' Seri Dr Noor Hisham Abdullah to get up to date with the COVID-19 situation in the country and to obtain his thoughts on the ramifications of the findings.

Empagliflozin advancing on all fronts: Readying for the future with EMPEROR

11 Aug 2020

In this final issue of our series, join us as we look into the upcoming results of the pivotal EMPEROR trials, which will investigate the use of empagliflozin in patients with either preserved or reduced ejection fraction heart failure, with or without type 2 diabetes. Understand why heart failure has such a high clinical burden, and the great unmet need in providing solutions for it.

Empagliflozin near to us: Insights from its use in Asians

09 Jul 2020

In this fourth issue, join us as we discover the unique biology Asians have with respect to diabetes. Take a closer look at trials evaluating whether empagliflozin’s cardiovascular and renal benefits – as analysed in Asians – are consistent with the overall trial population, and how it addresses unmet needs.

Early Treatment Intensification in T2DM, The Time is Now

29 Jun 2020

At the Novartis-sponsored VERIFY Soft Launch held at Le Meridien, Kuala Lumpur, two distinguished speakers spoke on the latest updates in glucose-lowering therapy and the benefit of early treatment intensification using combination therapy (ie, vildagliptin/metformin) in the management of T2DM.

Novel non-hormonal therapy may reduce hot flashes, improve QoL in postmenopausal women

Roshini Claire Anthony, 21 Oct 2020

NT-814, an oral, non-hormonal dual neurokinin 1,3 receptor antagonist may reduce the frequency of hot flashes, while improving quality of life (QoL) and sleep in postmenopausal women, according to results of the phase IIb SWITCH-1 trial presented at NAMS 2020.

Number, severity of menopausal symptoms may up CV risk

Roshini Claire Anthony, 19 Oct 2020

Women who experience two or more moderate or severe menopausal symptoms may have an elevated risk of cardiovascular disease (CVD) or strokes, according to a study presented at NAMS 2020.

Cycling may prevent deaths in diabetes patients

Pearl Toh, 15 Oct 2020

Cycling was associated with reduced risk for both all-cause and cardiovascular (CV) mortality in people with diabetes, according to a study presented at EASD 2020 Meeting — suggesting that cycling could be encouraged as an activity to prevent deaths in this population who are known to have a higher mortality risk than the general public.

Reducing T2D, obesity risk: Fast eaters should slow down

Audrey Abella, 15 Oct 2020

Fast eating increases post-prandial glucose (PPG) concentration and glycaemic excursion in young, healthy women without diabetes, an interventional study has shown, thus underscoring the role of eating speed in the development of type 2 diabetes (T2D) and obesity.

Increased exercise tied to lower mortality risk in adults with T2D

Elaine Soliven, 15 Oct 2020

Higher levels of exercise appear to be associated with a lower risk of all-cause mortality in adults with type 2 diabetes (T2D) compared with no exercise at all, according to a study presented at EASD 2020.